ABSTRACT Analysis of the many, sometimes seemingly contradictory, reports on the partial suppression of malignancy in highly unstable rodent intraspecies and rodent-human hybrid cells emphasizes the limitations of this approach to the analysis of the basic nature of malignancy, especially in naturally occurring human cancers. During the past 5 years, Stanbridge and then Klinger reported complete suppression, not elimination, of malignancy [defined as capacity to produce progressively growing tumors in athymic (nude) mice] in stable hybrids of different human cancer cells with normal human fibroblasts or with differentiating epithelial keratinocytes and, importantly, also in stable hybrids of two parental cancers of different somatic cell origin. The nontumorigenic human hybrid cells are not rejected by some nonthymic immune mechanism ofnude mice and survive in vascularized foci; the initial multiplication ofthese cells is stopped by some unknown proliferation controlling substance(s) to which their malignant parent(s) do not respond. The heritable properties of infinite multiplication in vitro, loss of contact inhibition, etc. remained in the nontumorigenic hybrids but, remarkably, the in vitro production of a human choriogonadotropin by HeLa cells was suppressed along with tumorigenicity and reappeared in the tumorigenic revertants. If it is assumed that human cancers of different somatic cell origin are caused by a loss of different specific regulatory genes, as the most recent data reviewed here suggest, the challenge is to determine in molecular terms what those missing genes are, how they function, and whether it may be possible to restore to the cancer cells what they have lost.
The complete suppression of malignancy in stable hybrids of human cancer cells with normal human fibroblasts first reported by Stanbridge (1) (ii) to call attention to the possibly important information that could emerge from a resolution of seemingly contradictory results reported by different investigators, and (iii) to indicate some of the many challenges that intraspecies human cell hybrids present for joint research among experimental oncologists, cytogeneticists, and molecular biologists to elucidate the nature of the malignant process in different human cancers by direct studies on naturally occurring human cancer cells rather than, as is so often done now, on experimental cancers that may bear little or no relationship to the great variety of human cancers.
Because transformation in vitro is not synonymous with tumorigenicity in vivo (4) (5) (6) , in the following discussion I use "malignancy" to refer only to the property of progressive tumorigenicity in vivo. Thus, "malignancy" relates to the capacity of a cell for continued multiplication in vivo when no more of it is needed and in parts of the body where it does not belong.
One of the important issues in the genesis of human cancers is whether this attribute is the result of acquisition of totally new genetic information (as in experimental cancers produced by viruses or by large doses of chemical carcinogens or radiation that result in extensive DNA damage followed by faulty repair) or ofa mutational malfunction or loss ofpreexisting specific regulatory suppressor genes (in the one cell from which the tumor arises) which prevent normal cells from behaving postnatally as they did during early embryonic development. Unstable suppression of malignancy in rodent intraspecies and rodent-human interspecies hybrids The elaborate studies on malignancy of hybrid cells of varying parentage that followed the new techniques of in vitro cell fusion developed by Harris and Watkins (7) were lucidly summarized in several publications (8) (9) (10) . The initial report of the collaborative studies by Harris and coworkers (11) provided the first evidence for what they called "suppression of malignancy by cell fusion." However, with some exceptions, what has been called "suppression of malignancy" in intraspecies or interspecies rodent hybrids has not been a complete absence of tumorigenicity of the cultured hybrid cells but rather a graded character that was measured by the number of cells required to produce progressively growing tumors in irradiated immunologically permissive histocompatible mice-i.e., much larger numbers ofthe hybrid cells than of the highly malignant parent cells had to be injected in order to obtain progressively growing tumors in 50-100% of the mice. Similar findings were also reported shortly thereafter by Ephrussi et at (12) . The need for much larger numbers ofinitially cultured hybrid cells to produce tumors that consisted of hybrid cells was interpreted as indicating that malignancy was completely suppressed in the hybrid cells with a full or nearly full complement of chromosomes from both parental cells and that the tumors resulted from the in vivo selection of the hybrid cells that had lost certain chromosomes and were just as malignant as the highly malignant parent (8, 11) . Because there was great variation in the total number of chromosomes that were found in the hybrid tumor cells, it was postulated that reversion to malignancy depended not on the loss of a special number of chromosomes but rather on the loss ofcertain specific chromosomes which carried the hypothetical normal suppressor genes (13) . Based on this interpretation of the observed gradation of malignancy in various hybrid cell populations, Harris (8) It is noteworthy that the quantitative malignancy suppressive effects referred to above were obtained with naturally occurring mouse tumors as well as with mouse tumors experimentally produced by viruses or chemicals (8) (9) (10) (11) . These results with mouse tumors of different origin and the absence of tumorigenicity, in nude mice, of human cells experimentally transformed by the Epstein-Barr virus and simian virus 40 (SV40) (4) led Klein (6) to suggest that, whereas certain viruses and chemical carcinogens can transform cells to become "immortal" and to exhibit other abnormal properties in vitro, they are not per se responsible for tumorigenicity in vivo, which appears to depend on additional cellular changes that result in "resistance to negative feedback regulation of the host."
The reports of Croce, Koprowski, and Aden (14, 15) that incorporation of the SV40 genome can by itself confer tumorigenicity because malignancy was not suppressed in hybrids of SV40-transformed human cells with normal mouse cells, which retain a full complement ofmouse chromosomes and only a few human chromosomes or even a single human chromosome, are not in accord with the above postulate, even ifone assumes that normal mouse cells transformed by SV40 would regularly produce progressively growing tumors in nude mice. Using irradiated, newborn histocompatible mice instead of nude mice in their tests for tumorigenicity, Gee and Harris (5) found that not only were SV40-transformed mouse fibroblasts usually not tumorigenic but also such transformed mouse cells were able to suppress tumorigenicity completely in hybrids with a highly malignant mouse melanoma; moreover, they also demonstrated that in tumorigenic SV40-transformed mouse cells it was possible to suppress this tumorigenicity by hybridization with normal mouse fibroblasts. Gee and Harris (5) were inclined to attribute the discrepant data of Croce, Koprowski, and Aden (14, 15) to their use of 107-108 cells in their tests for tumorigenicity because the small number of tumors resulting from these large numbers of hybrid cells could have been due to an in vivo selection of rare malignant variants. This may or may not be the whole explanation, and the assumption that naturally occurring cancers and experimental cancers artificially produced by viruses or chemicals have the same ultimate defects responsible for malignancy needs to be resolved by further work. For example, the DNA of chemically transformed malignant mouse and rat cells has recently been reported to transform normal mouse cells to malignancy (16) , in the presence of normal "suppressor genes" unless they were destroyed by the manipulation required to get the DNA into the cells-a possibility that can and should be tested.
The capacity of cultured mouse embryo fibroblasts (at 2-4 X 10' cells) to suppress malignancy completely in some clones of hybrids with a highly malignant mouse melanoma was demonstrated in well-controlled studies by Jonasson et al. (17) . Accordingly, it is especially meaningful (and potentially highly informative) that Halaban et al. (18) found no suppression of malignancy (at least at 1 x 106 cells per mouse, the only dosage tested) in clones of another malignant mouse melanoma with normal mouse melanocytes that appeared spontaneously in tumors produced in newborn mice or experimentally after in vitro fusion with skin cells of 1-day-old mice. In one such hybrid clone the full complement of parental chromosomes was present in the cultured cells before they were inoculated into mice and in the tumors these cells produced. It is noteworthy that the normal, nonmalignant parents ofthese hybrids were differentiating melanocytes and not fibroblasts, which raises the important question whether normal differentiating cells may have no functioning malignancy suppressor genes at the time they are undergoing differentiation.
More difficult to interpret, however, is the apparent absence of suppression in spontaneous in vivo hybrids with a full complement of parental chromosomes that appeared in mouse fibrosarcoma tumors in 3-month-old syngeneic mice (19) .
In 1978, Koprowski et al. (20) reported that a hybrid of a tumorigenic human melanoma with nontumorigenic mouse fibroblasts was tumorigenic in nude mice even when only human chromosomes 14, 17, and 21 remained. One year later, Carney et al. (21) reported that 14 independent clones ofhybrids oftumorigenic human lung cancer cells and nontumorigenic mouse embryofibroblasts were completely nontumorigenic in 77 nude mice (each inoculated with 4-12 X 106 hybrid cells). The presence of many human chromosomes in these hybrids was established by isoenzyme markers. Is it possible that the human chromosomes carrying the derepressed genes for the human lung cancer were lost in all the clones tested by Carney et al. (21) and that the few human chromosomes that remained in the melanoma hybrid cells tested by Koprowski et al. (20) retained the derepressed genes responsible for the malignancy of the melanoma, and that normal mouse fibroblasts cannot suppress human malignancies because "malignancy suppressor genes" are species-specific? Or is it possible that the normal mouse fibroblasts used by Carney et al. (21) contained "malignancy suppressor genes" while those of Koprowski et al. (20) did not?
The same issue arises in hybrids between malignant mouse tumors and normal human fibroblasts. In 1977, Jonasson and Harris (22) reported that hybrids of a highly malignant mouse melanoma and their line ofnormal human fibroblasts were nontumorigenic in nude mice even in a clone in which only one human chromosome (an X chromosome) was left. Two years later, Kucherlapati and Shin (23) reported the opposite for hybrids of the same mouse melanoma and also of another mouse cancer with two different lines ofnormal human fibroblasts (but they did not test the lines used by Jonasson and Harris). They found that 19 independently arising clones were uniformly tumorigenic in nude mice (although more hybrid cells than malignant parent cells were required to produce tumors), despite the demonstration by cytological and isoenzyme analysis that at least 14 of the 23 human chromosomes were retained both in the original hybrids and in the progressively growing tumors in nude mice. Here again, one faces the issue ofpossible species specificity of the suppressor gene(s) or that the remaining normal human chromosomes did not carry the required complement of suppressor genes.
The extensive and detailed chromosomal and tumorigenicity studies on many cloned hybrids derived from "spontaneous" malignant mouse or Chinese hamster tumors and different normal human fibroblasts by Klinger and his associates (2, 24, 25) indicated that "no human chromosome in single copy appears to be able to greatly affect tumorigenicity" but "many hybrids, particularly those with many human chromosomes, require higher cell inocula or longer periods oftime to form tumors than do the heteroploid parental lines." Moreover, their data also showed that certain combinations of chromosomes from the normal human cells were never found in tumors produced by the hybrid cells, and one or more combinations were always present in the suppressed hybrids. The most effective suppressor combinations appeared to be the normal human chromosomes 9 and 17, 11 and 13, and 11 and 17. These observations do not account for the unusual finding by Jonasson and Harris (22) , but they led Klinger to the tentative conclusion "that at least two mutations are required for a cell to undergo malignant transformation" (25) and that "genes on at least two chromosomes appear to be required for suppression" (24) .
Quite different results were reported by Bloch-Shtacher and (1, 29) . Thus, even individual cells that had only 86-90 chromosomes were not selected for tumorigenicity in vivo. During subsequent cultivation over a period of 2 years, there was no further loss of chromosomes, and the hybrid cell lines remained nontumorigenic. However, the nontumorigenic hybrids, which morphologically were intermediate between the epithelial malignant cells and the fibroblastic normal parents, retained the following in vitro properties oftransformation exhibited by the malignant but not the normal parent cells: (i) capacity to multiply indefinitely (i.e., "immortality"); (ii) absence of contact inhibition; (iii) anchorage-independent growth (colonies in soft agar); and (iv) lectin agglutination, decreased requirement for serum factors, alterations in expressions ofvarious cell surface components, and production of alkaline phosphatase. However, the capacity of the HeLa cells to produce a human choriogonadotropin (ahCG) in vitro was lost by the nontumorigenic hybrids by (E. J. Stanbridge, personal communication, work with H. Sussman). After many months of continuous cultivation, rare morphologically altered subpopulations were isolated from three HeLa-fibroblast hybrid lines, and these formed progressively growing tumors in nude mice inoculated with 5 x 105 cells (31, 32). These tumorigenic revertants, which had lost c5% of the total biparental chromosome complement (32) , were morphologically like the HeLa cells and had regained the capacity to produce ahCG in vitro (E. J. Stanbridge, personal communication). This linkage between in vitro production of ahCG and tumorigenicity is of special interest because either the same genes are responsible for both or different genes close together on the same chromosome(s) are absent from or inactive in the tumorigenic cell and can be suppressed by active genes in normal cells. Chromosomal analysis of the tumorigenic revertant cells showed "that the loss ofone copy* of chromosomes 11 and 14, respectively, is correlated with a high degree of statistical significance, to the expression of tumorigenicity" (32) . This finding is of special interest because of the previous demonstration by Klinger et al. (2, 24, 25) of the suppressive role of normal human chromosome 11 (although only in combination with chromosome 13 or 17) in interspecies hybrids with mouse and hamster malignant tumors.
All the phenomena reported by Stanbridge et al. were fully confirmed and extended by Klinger et al. (2, 3) who did not test for ahCG production. They used a clonal derivative from the same line ofHeLa cells used by Stanbridge but different normal human cells (male fetal fibroblasts) which had nine distinctive chromosomes that could be identified in the hybrids. All their hybrids remained completely nontumorigenic after subcloning and prolonged culture. They showed that nontumorigenic hybrids were also obtained even when HeLa cells derived from a nude mouse tumor were used for hybridization, thus eliminating the possibility of hybrids being formed preferentially from a subpopulation of nontumorigenic cells. By recovering rare tumorigenic variants from cloned populations of nontumorigenic hybrids, they also showed that tumorigenicity in the hybrids was only suppressed and not eliminated by the hybridization procedures. These revertant cells had lost only a small number ofchromosomes, primarily those ofthe distinguishable normal parent chromosomes,t which led Klinger (3) to conclude: "only specific chromosomes can carry such [suppressive] information, since other isolates with equally low chromosome numbers were not tumorigenic." Validity of assumption that tumorigenicity in nude mice is an indicator of malignancy instead of immunologic rejection by nonthymic mechanisms Because nude mice have been shown to have high levels ofnatural cell-mediated cytotoxic or natural killer (NK) activity which has been reported to inhibit proliferation of some mouse lymphoid tumors (33, 34) , and because the suitability of nude mice as indicators of malignancy has been recently questioned (35) (36) (37) , Stanbridge and Ceredig (38) carried out an extensive study on their nontumorigenic hybrids and the revertant tumorigenic segregants derived from them, which showed the following.
(i) During the first 3 days after injection, there was no histologic difference between the nontumorigenic and tumorigenic cell foci; within 24 hr, both showed extensive central necrosis surrounded by a rim of intact cells with many mitotic figures.
(ii) On day 4, mitotic activity ceased in the nontumorigenic cells which assumed a fibroblastoid morphology and did not multiply further; the focus of remaining cells was vascularized, there was no inflammatory response or other cellular infiltration, and the cells were alive as was evident by their multiplication in vitro.
(iii) Mitotic activity remained very active in the tumorigenic cells, and progressively growing tumors developed.
(iv) Nontumorigenic hybrid cells produced no tumors in neonatal or heavily irradiated nude mice which lack NK cells and other immune mechanisms.
* The three remaining copies may have been from the malignant parent in which the suppressor genes had been lost or nonfunctional.
t Data as to which normal chromosomes were lacking in the revertants
are not yet available.
Medical Sciences: Sabin (v) Nontumorigenic hybrids and the tumorigenic segregants were equally susceptible to the cytotoxic action of NK cells of nude mice in vitro, but when NK cell activity was induced in nude mice by C. parvum vaccine, the tumorigenic segregants still formed tumors.
(vi) Tumor-derived hybrid cells were also sensitive to NK cell toxicity in vitro, indicating that the tumors are not made up of cells that are selected for resistance to NK cell toxicity.
(vii) Injection ofa mixture consisting of 90% nontumorigenic hybrid cells and 10% tumorigenic cells did not prevent tumor formation, indicating that the nontumorigenic hybrid cells did not induce a nonthymic immune response to the tumorigenic segregants derived from them.
These experiments indicate that these human cancer cells that are tumorigenic in nude mice have lost the something that permits a response to the proliferation inhibitory substance(s) produced by nude mice in vivo which stopped the proliferation of their nontumorigenic hybrid clonal relatives. The nontumorigenic hybrid cells have regained the genes responsible for this feedback response property ofnormal cells, despite the fact that they still had the capacity for infinite multiplication in vitro-i. e., immortality. Whether or not the in vitro transformed properties of immortality, absence of contact inhibition, etc. that have been found by Stanbridge et aL (1, 29) and Klinger (3) to be present in all the nontumorigenic hybrid cells represent necessary preliminary stages ("precancerous") in the progression to malignancy, it would appear that the mechanism of the production of these heritable properties is different from that involved in the ultimate production of malignancy which can be completely suppressed by hybridization with normal cells while the transformation properties detected in vitro except for the production of ahCG are not suppressed. Can malignancy of other human cancers also be suppressed by hybridization with normal human fibroblasts?
According to Stanbridge (personal communication), hybrids of human lung carcinoma-(A549) and of endometrial carcinoma cells, having modal chromosome numbers of 63 and 51, respectively, with normal human fibroblasts have also yielded nontumorigenic hybirds. However, special problems were encountered in hybridization tests with the human sarcoma HT1080 which has cells with pseudodiploid and tetraploid numbers of chromosomes. Stanbridge found that, when pseudodiploid clones of HT1080 were used for fusion with normal fibroblasts, the hybrids usually did not proliferate sufficiently in vitro to provide enough cells for tumorigenicity tests. However, one such hybrid did proliferate enough and its tumorigenicity was suppressed. Hybrids with tetraploid clones of HT1080 human sarcoma proliferated adequately in vitro but tumorigenicity was not suppressed. Croce et aL (39) , also working with HT1080 human sarcoma and different lines of human diploid fibroblasts, succeeded-in obtaining proliferating hybrids with pseudodiploid sarcoma cells: these hybrid cells, which apparently contained the full complement of chromosomes from the sarcoma and normal cells, were uniformly tumorigenic when 5 X 106 or 107 cells were injected in nude mice, although they also counted nonprogressive nodules >5 mm in diameter without further growth during 2 or more months as tumors. They reported that "karyologic analysis of the tumorigenic hybrid cells recovered from the tumors indicated that these cells were either near tetraploid or near hexaploid human hybrid cells." This is a problem that obviously needs to be resolved, especially the failure of normal fibroblasts to achieve suppression of the tetraploid HT1080 human sarcoma. Complementation in hybrids derived from human cancers of different somatic cel origin Harris (8) (41) . Peehl and Stanbridge (41) produced many hybrids of such primary epithelial cells with HeLa cells and found, first of all, that the capacity of the HeLa cells to form progressively growing tumors in nude mice was completely suppressed in the hybrids. However,initially or after many subsequent population doublings, some ofthe hybrid clones produced nonprogressive nodules only a few millimeters in diameter at some of the subcutaneous sites in which 1O6-107 hybrid cells were inoculated. Histologically, these nodules had the appearance of differentiated squamous cell carcinomas with few or no dividing cells. According to Peehl and Stanbridge "the key question is whether these nodules represent bona fide tumors or whether they are the result of a growth regulatory signal mediated by the host which switches the dividing HeLa-keratinocyte hybrids into a differentiated, non-dividing state." In any case, these nonmalignant hybrids provide still another opportunity for analysis of malignancy in human cancer cells. Some challenges The work already done during the past 5 years by both Stanbridge and Klinger and their associates on the complete suppression ofmalignancy in stable hybrids ofdifferent human cancers with normal cells and also with cancers of different somatic cell origin have provided strong evidence for the concept that malignancy in human cancer cells is the result of a loss or malfunction ofdifferent specific regulatory genes that are present in normal somatic cells. The use of such stable, nontumorigenic hybrids provides hitherto unexplored possibilities for research directly on human cancers. Here are only a few of the many challenges that come to mind.
1. Use available technology (42, 43) to determine whether certain metaphase chromosomes from normal fibroblasts can be incorporated into HeLa cells and which ones or how many are needed to suppress their malignancy. Changes in morphology and failure to produce ahCG in vitro could serve as screens.
2. Use the same technique to determine whether the transfer of certain chromosomes from HeLa cells to normal fibroblasts and nontumorigenic hybrids will induce malignancy in one or the other or both, or not at all.
3. Determine whether transfer of malignancy to normal human fibroblasts can be achieved with sonicated DNA from HeLa cells as it was done with DNA from methylcholanthrene-induced mouse cancer cells, spontaneous mouse, and human carcinoma to normal mouse fibroblasts (16, 44) . 4 . Determine whether sonicated DNA from normal human fibroblasts can suppress malignancy ofHeLa cells. Ifso, it would be possible to use restriction enzymes to determine which piece(s) carry the postulated suppressor genes.
5. How do suppressor genes in normal chromosomes that are present (but not as alleles) in the nuclei of nontumorigenic hybrids suppress the malignancy expressed by the genes in the derepressed chromosomes from the malignant parent? If suppressor RNA or protein can be identified, explore possibilities ofpreparing it in large amounts and ofgetting it into cancer cells during the early stages of progressive growth in nude mice. 6 . Test many more varieties of human cancer for their capacity to be suppressed by hybridization with normal human cells, and determine the role of naturally integrated viral genome in some ofthem-for example, can the malignancy in cells from primary hepatocellular carcinoma with integrated hepatitis B virus genome be suppressed as well as that in cells without this genome, assuming that suppression can be achieved at all with these cancer cells?
7. In view ofthe remarkable parallelism between suppression of malignancy in vivo and suppression of production of ahCG in vitro in hybrids of HeLa cells and normal human cells, determine whether ahCG may be the substance that is responsible for the failure of the malignant HeLa cells to respond to the in vivo proliferation-inhibiting factor(s) by testing the effect of anti-ahCG agents on the progressive multiplication of HeLa cells in nude mice.
